Stockscreener 앱 받기
9.84
2.77%
-0.28
전일 마감가:
$10.12
열려 있는:
$10.57
하루 거래량:
2.32M
Relative Volume:
2.06
시가총액:
$433.94M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+47.09%
1개월 성능:
+64.27%
6개월 성능:
-56.32%
1년 성능:
+0.00%
1일 변동 폭
$9.52
$10.87
1주일 범위
$6.44
$11.36
52주 변동 폭
$4.17
$28.99
Septerna Inc Stock (SEPN) Company Profile
명칭
Septerna Inc
전화
650-338-3533
주소
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
SEPN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
9.84 | 297.81M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-19 | 개시 | JP Morgan | Overweight |
| 2024-11-19 | 개시 | TD Cowen | Buy |
| 2024-11-19 | 개시 | Wells Fargo | Overweight |
Septerna Inc 주식(SEPN)의 최신 뉴스
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - MSN
Septerna: Novo's Investment In Incretin Program IntriguesOne For The Watchlist - Seeking Alpha
Where Septerna Stands With Analysts - Benzinga
Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash - Seeking Alpha
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight - Investing.com
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership - PMLiVE
Septerna price target raised to $18 from $11 at Wells Fargo - TipRanks
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - MSN
Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating - TipRanks
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Septerna reports Q1 EPS (49c), consensus (45c) - TipRanks
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - The Manila Times
Septerna Lands Massive $2.2B Novo Nordisk Partnership to Revolutionize Oral Diabetes and Obesity Treatments - Stock Titan
Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal - MSN
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled - MSN
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk - MSN
ETFs to Capitalize on the Novo Nordisk-Septerna Deal - Yahoo Finance
Is It Time to Buy the Dip in Novo Nordisk Stock? - Investing.com
Novo Nordisk, Septerna collaborate on developing GPCR therapies - World Pharmaceutical Frontiers
Novo Nordisk Partners with Septerna for New Obesity Drug Development - GuruFocus
Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal - Law360
Novo Nordisk Looks To Septerna For Oral Obesity Options - insights.citeline.com
Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal - MSN
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal - Yahoo Finance
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside | FinancialContent - FinancialContent
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies - Pharmaceutical Technology
This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent - MSN
Septerna Stock Spikes on Novo Nordisk Obesity Drug Deal - Wall Street Pit
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B - BioSpace
Peninsula biotech Septerna lands deal for oral GLP-1 weight-loss drugs, stock zooms higher - The Business Journals
Novo Nordisk (NVO) Partners with Septerna to Develop Obesity and Diabetes Drugs - GuruFocus
Novo Nordisk Rises on Weight-Loss Deal. Septerna Stock Gains Even More. - Barron's
Septerna and Novo Nordisk to collaborate on oral obesity and other cardiometabolic diseases - The Pharma Letter
Novo Nordisk in pact with Septerna for oral obesity drugs - MSN
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
First patient treated with prime editing - statnews.com
Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill - Yahoo Finance
Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal (SEPN) - Bloomberg.com
$2.2 billion deal: Septerna and Novo Nordisk collaborate on obesity, cardiometabolic diseases - PharmaLive
novo-nordisk-partners-with-septerna-on-obesity-drugs - baha.com
Novo makes fresh obesity play with $2.2bn Septerna deal - Pharmaphorum
Novo Nordisk partners with Septerna on obesity drugs - breakingthenews.net
Novo to work with Septerna in hunt for oral obesity drugs - Yahoo Finance
Septerna jumps 60% after Novo Nordisk partnership to develop oral obesity drugs - TradingView
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies - Proactive financial news
Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases - marketscreener.com
Septerna Enters Major Collaboration with Novo Nordisk - TipRanks
Septerna Inc (SEPN) 재무 분석
Septerna Inc (SEPN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Septerna Inc 주식 (SEPN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Finer Jeffrey | CEO and President |
Apr 03 '25 |
Option Exercise |
2.76 |
5,000 |
13,800 |
826,907 |
| Ezekowitz Alan | Director |
Mar 07 '25 |
Buy |
6.93 |
13,319 |
92,270 |
117,420 |
| Ezekowitz Alan | Director |
Mar 06 '25 |
Buy |
6.00 |
41,355 |
248,130 |
104,101 |
| Ezekowitz Alan | Director |
Mar 05 '25 |
Buy |
5.82 |
37,835 |
220,260 |
62,746 |
| Ezekowitz Alan | Director |
Mar 04 '25 |
Buy |
6.35 |
7,491 |
47,544 |
24,911 |
| Finer Jeffrey | CEO and President |
Feb 25 '25 |
Buy |
5.68 |
10,000 |
56,765 |
764,907 |
| Finer Jeffrey | CEO and President |
Feb 26 '25 |
Buy |
5.70 |
4,000 |
22,796 |
768,907 |
| Finer Jeffrey | CEO and President |
Feb 27 '25 |
Buy |
5.80 |
3,000 |
17,400 |
771,907 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 25 '25 |
Buy |
5.59 |
6,282 |
35,116 |
36,282 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 27 '25 |
Buy |
5.85 |
3,718 |
21,750 |
40,000 |
1.54%
7.58%
자본화:
|
볼륨(24시간):